Cipla said the acquisition is a strategic move aimed at integrating Inzpera’s differentiated portfolio of paediatric pharmaceutical and wellness products with Cipla’s strong distribution network and operational capabilities to drive growth and scalability. Shares of Cipla Ltd ended at ₹1,511.60, up by ₹9.95, or 0.66%, on the BSE.
